Illumina delivers results, growth plans at JP Morgan Healthcare Conference

By The Science Advisory Board staff writers

January 18, 2022 -- Illumina's CEO, Francis deSouza, discussed the company's growth trajectory, including 2021 results and 2022 guidance at the 2022 virtual J.P Morgan Healthcare Conference. The company also announced new partnerships and technologies to advance its mission of improving human health by unlocking the power of the genome.

Illumina delivered a strong finish to 2021, with preliminary consolidated fourth quarter revenue of approximately $1.19 billion, up 25% year over year. Illumina also delivered a preliminary fiscal year 2021 consolidated revenue of approximately $4.517 billion, up 39% year over year. The company expects another strong year in 2022.

Illumina has formed new collaborations with Agendia, Boehringer Ingelheim, Optum, and Nashville Biosciences to accelerate access, utilization, and discovery for genomics, deSouza said.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.